Entity
  • Cellectis

    Created in 1999
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    4,549 43,278
  • Activities

  • Technologies

  • Entity types

  • Location

    8 Rue de la Croix Jarry, 75013 Paris, France

    Paris

    France

  • Employees

    Scale: 51-200

    Estimated: 232

  • SIREN

    428859052
  • Engaged corporates

    19
    6 8
  • Added in Motherbase

    5 years, 4 months ago
Description
  • Value proposition


    Cellectis is developing life-changing product candidates to target and eradicate cancer cells.


    Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

    With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

    Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

    We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).

    We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

    At Cellectis, we are committed to a cure.

    Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

    To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

    Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .

    (*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

    TALEN® is a registered trademark owned by the Cellectis Group.

    Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, and off-the-shef CART therapies

  • Original language


    Cellectis is developing life-changing product candidates to target and eradicate cancer cells.


    Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

    With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

    Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

    We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).

    We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

    At Cellectis, we are committed to a cure.

    Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

    To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

    Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .

    (*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

    TALEN® is a registered trademark owned by the Cellectis Group.

  • Home | Cellectis

    Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer

  • https://www.cellectis.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Servier Pharmaceuticals
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing
Not capitalistic
Partnership
Event

1 Jun 2020


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

2 Nov 2016


Bayer
Bayer
Pharmaceutical, Chemistry, Chemical Manufacturing
Bayer
Pharmaceutical, Chemistry, Chemical Manufacturing
Not capitalistic
Partnership
Not event

30 Jan 2014


BFM Business
BFM Business
Media, Broadcast Media Production and Distribution
BFM Business
Media, Broadcast Media Production and Distribution
Other

6 Apr 2021

9 May 2024



Moderna
Moderna
Pharmaceutical, Biotechnology, Biotechnology Research
Moderna
Pharmaceutical, Biotechnology, Biotechnology Research
Not capitalistic
Not partnership
Event

15 Jan 2021


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Not capitalistic
Partnership
Not event

11 May 2021

24 Apr 2023



HEC Paris
HEC Paris
Higher Education
HEC Paris
Higher Education
Not capitalistic
Partnership
Not event

10 Dec 2020

18 Sep 2024



Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Not capitalistic
Not partnership
Event

5 Oct 2021


L'Express
L'Express
Media, Newspaper Publishing
L'Express
Media, Newspaper Publishing
Not capitalistic
Not partnership
Event

4 Nov 2021

27 Nov 2023



Similar entities
Loading...
Loading...
Social network dynamics